Procyrion is focused on developing the Aortix™, a percutaneous mechanical circulatory support (pMCS) device aimed at treating heart failure patients who are not adequately managed with medication alone. This innovative device is designed to reduce cardiac workload and enhance renal perfusion, addressing a critical issue known as cardiorenal syndrome, which affects a significant number of heart failure patients. The Aortix™ operates by allowing a portion of the native blood flow to enter the pump, where high-velocity jets increase the overall velocity and aortic flow, ultimately improving blood circulation and kidney function.

Currently, the Aortix™ device is in the research and development phase and is undergoing clinical trials to evaluate its effectiveness in various patient populations, including those with acute decompensated heart failure and persistent congestion. Procyrion's commitment to addressing the unmet clinical needs of heart failure patients is underscored by their recognition as a Fierce15 Medtech company, highlighting the potential impact of their technology on the treatment landscape for heart failure and related conditions.

United States

Procyrion is dedicated to improving outcomes for patients with cardiac and renal impairment using its catheter-deployed pump technology to address conditions with significant unmet needs. Aortix™ is a percutaneous mechanical circulatory support device that treats cardiorenal syndrome with a rapidly-deployed intra-aortic catheter-based system.

Aortix™ is currently in the research and development phase and is not available for sale in any country.
(Caution: investigational device. Limited by federal law to investigational use.)

Procyrion

Company Details